XML 39 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration and License Agreements (Tables)
6 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Revenue
The following table provides a summary of revenue recognized:
Three Months Ended March 31,Six Months Ended March 31,
2023202220232022
(in thousands)
GSK$30,000 $120,000 $29,323 $120,000 
Horizon— 7,918 21,667 14,585 
Takeda116,156 20,821 132,468 41,593 
Janssen111 3,066 355 3,066 
Amgen— — 25,000 — 
Total$146,267 $151,805 $208,813 $179,244 
Schedule of Receivables and Contract Liabilities
The following table summarizes the balance of receivables and contract liabilities related to the Company’s collaboration and license agreements:
March 31, 2023September 30, 2022
(in thousands)
Receivables included in accounts receivable$70,000 $6,174 
Contract liabilities included in deferred revenue$30,914 $130,049